Suppr超能文献

贝沙罗汀调节维 A 酸 X 受体的表达,并能防止神经毒性内质网应激反应和凋亡途径的激活。

Bexarotene Modulates Retinoid-X-Receptor Expression and Is Protective Against Neurotoxic Endoplasmic Reticulum Stress Response and Apoptotic Pathway Activation.

机构信息

Faculty of Medicine and Health Sciences, Macquarie University, F10A, 2 Technology Place, North Ryde, NSW, 2109, Australia.

School of Medical Sciences, Edith Cowan University, Perth, Australia.

出版信息

Mol Neurobiol. 2018 Dec;55(12):9043-9056. doi: 10.1007/s12035-018-1041-9. Epub 2018 Apr 10.

Abstract

Retinoid X-receptors (RXRs) are members of the ligand-dependent transcription factor family of nuclear receptors that have gained recent research focus as potential targets for neurodegenerative disorders. Bexarotene is an RXR pharmacological agonist that is shown to be neuroprotective through its effects in promoting amyloid beta (Aβ) uptake by the glial cells in the brain. This study aimed to evaluate the dose-dependent effects of bexarotene on RXR expression in SH-SY5Y neuroblastoma cells and validate the drug effects in the brain in vivo. The protein expression studies were carried out using a combination of various drug treatment paradigms followed by expression analysis using Western blotting and immunofluorescence. Our study demonstrated that bexarotene promoted the expression of RXR α, β and γ isoforms at optimal concentrations in the cells and in the mice brain. Interestingly, a decreased RXR expression was identified in Alzheimer's disease mouse model and in the cells that were treated with Aβ. Bexarotene treatment not only rescued the RXR expression loss caused by Aβ treatment (p < 0.05) but also protected the cells against Aβ-induced ER stress (p < 0.05) and pro-apoptotic BAD protein activation (p < 0.05). In contrast, higher concentrations of bexarotene upregulated the ER stress proteins and led to BAD activation. Our study revealed that these downstream neurotoxic effects of high drug concentrations could be prevented by pharmacological targeting of the TrkB receptor. The ER stress and BAD activation induced by high concentrations of bexarotene were rescued by the TrkB agonist, 7,8 dihydroxyflavone (p < 0.05) while TrkB inhibitor CTX-B treatment further exacerbated these effects. Together, these findings suggest a cross-talk of TrkB signalling with downstream effects of bexarotene toxicity and indicate that therapeutic targeting of RXRs could prevent the Aβ-induced molecular neurotoxic effects.

摘要

视黄酸 X 受体 (RXRs) 是配体依赖性转录因子家族核受体的成员,作为神经退行性疾病的潜在靶点,最近受到了研究关注。倍他罗汀是一种 RXR 药理学激动剂,通过促进胶质细胞摄取淀粉样蛋白 β (Aβ) 显示出神经保护作用。本研究旨在评估倍他罗汀在 SH-SY5Y 神经母细胞瘤细胞中对 RXR 表达的剂量依赖性影响,并验证体内药物在大脑中的作用。使用各种药物处理方案的组合进行蛋白表达研究,然后使用 Western blot 和免疫荧光进行表达分析。我们的研究表明,倍他罗汀在细胞和小鼠大脑中以最佳浓度促进 RXRα、β 和γ 同工型的表达。有趣的是,在阿尔茨海默病小鼠模型和 Aβ 处理的细胞中发现 RXR 表达减少。倍他罗汀治疗不仅挽救了 Aβ 处理引起的 RXR 表达丧失(p<0.05),而且还保护细胞免受 Aβ 诱导的内质网应激(p<0.05)和促凋亡 BAD 蛋白激活(p<0.05)。相比之下,较高浓度的倍他罗汀上调内质网应激蛋白并导致 BAD 激活。我们的研究表明,这些高药物浓度的下游神经毒性作用可以通过靶向 TrkB 受体进行药理学靶向来预防。高浓度倍他罗汀诱导的内质网应激和 BAD 激活通过 TrkB 激动剂 7,8 二羟基黄酮(p<0.05)得到挽救,而 TrkB 抑制剂 CTX-B 处理进一步加剧了这些作用。总之,这些发现表明 TrkB 信号转导与倍他罗汀毒性的下游效应存在交叉对话,并表明 RXR 的治疗靶向可能预防 Aβ 诱导的分子神经毒性效应。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验